iTeos Therapeutics, Inc. ITOS
Set alert
At close · Aug 29
52-week range unavailable
- YTD
- +32.16%
- 1 year
- -40.82%
- Open
- 10.15
- Prev close
- 10.15
- Mkt cap
- 268.52M
- Vol
- 11.01M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.15
- High
- 10.15
- Forward P/E
- -1.26
- Beta
- 1.39
- Short ratio
- 3.66
- Inst. own
- 103.92%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 8.57
- 200-d avg
- 12.79
- 1y target
- 25.00
3M chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Aug 28, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 20, 2025 | 1 year ago |
| SMA: Bullish | Aug 19, 2025 | 1 year ago |
| SMA: Bearish | Aug 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 31, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| RSI: Overbought | Jun 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
Key statistics
- Market cap
- 268.52M
- Enterprise value
- -212.10M
- Trailing P/E
- 0.00
- Forward P/E
- -1.26
- PEG ratio
- 0.00
- Price / sales
- 7.67
- Price / book
- 0.43
- EPS (TTM)
- -3.14
- Beta
- 1.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 35.00M
- Revenue growth
- 0.00%
- Free cash flow
- -90.69M
- Total cash
- 488.71M
- Total debt
- 5.53M
- Return on equity
- -19.72%
- Shares outstanding
- 36.53M
- Short % of float
- 10.05%
- 50-day average
- 8.57
- 200-day average
- 12.79
Analyst view
Consensus: strong buy
- Target (low)
- 16.00
- Target (mean)
- 25.00
- Target (high)
- 47.00
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -1.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -1.18 | -1.05 | +0.13 | +11.02% |
| Aug 8, 2024 | Jun 1, 2024 | -1.04 | -0.18 | +0.86 | +82.69% |
| Aug 8, 2024 | Jun 1, 2024 | -1.04 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | -1.02 | -1.07 | -0.05 | -4.90% |
| May 10, 2024 | Mar 1, 2024 | -1.02 | — | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -1.03 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | main | Overweight | Overweight |
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | Wells Fargo | init | — | Overweight |
| Aug 12, 2024 | JP Morgan | main | Overweight | Overweight |
About iTeos Therapeutics, Inc.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- iteostherapeutics.com
News
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of Shareholders
- ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
- ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)
- ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders
- iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
- iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
- iTeos Therapeutics Announces Its Intention to Wind Down Operations
Your note
Sign in to keep a note on ITOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOXER CAPITAL L L C | Unknown | Stock Award(Grant) | May 9, 2024 | 0 |
| CALL MATTHEW A MBA | Chief Operating Officer | Stock Award(Grant) | Dec 4, 2023 | 137,898 |
| DETHEUX MICHEL | Chief Executive Officer | Stock Award(Grant) | Dec 4, 2023 | 58,903 |
| FELTQUATE DAVID M.D., PH.D. | Officer | Stock Award(Grant) | Dec 5, 2024 | 47,000 |
| GALL MATTHEW | Chief Financial Officer | Purchase | Nov 18, 2024 | 65,429 |
| MCGRATH YVONNE | Officer | Stock Award(Grant) | Dec 4, 2023 | 31,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.63% | 3,882,549 | 28.54M | Sep 29, 2024 |
| RA Capital Management, L.P. | 8.72% | 3,184,711 | 23.41M | Sep 29, 2024 |
| Boxer Capital, LLC | 8.07% | 2,946,915 | 21.66M | Sep 29, 2024 |
| MPM Asset Management, LLC | 7.50% | 2,738,785 | 20.13M | Sep 29, 2024 |
| Tang Capital Management, LLC | 6.59% | 2,407,800 | 17.70M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 4.78% | 1,745,943 | 12.83M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.34% | 855,645 | 6.29M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.84% | 671,531 | 4.94M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.57% | 572,858 | 4.21M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.17% | 426,251 | 3.13M | Sep 29, 2024 |
| BlackRock Advantage Small Cap Core Fund | 1.11% | 405,245 | 2.98M | Aug 30, 2024 |
| Fidelity Small Cap Index Fund | 0.72% | 264,212 | 1.94M | Aug 30, 2024 |